Novo Holdings — 2026 Investments
4 investments dated 2026 · listed companies and verified rows first · show all
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalInVivium CapitalNorwest Venture PartnersRiverVest Venture Partners+7 more
Claris Bio is a late-stage therapeutics company developing pharmacologic treatments for sight-threatening ophthalmic conditions with no or limited treatment options.
BiotechHealthtech
Co-investorsRA CapitalSofinnova Ventures
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)
Co-investorsLongwood FundSofinnova VenturesBAM ElevateFinchley Healthcare VenturesForbionLuma Group+1 more
Terremoto Bio develops next-generation small-molecule therapies using medicinal chemistry, targeting previously "undruggable" disease areas.
BiotechDeep TechSouth San Francisco, US
Grace Lu(Executive Officer)James Christensen(Executive Officer, Director)Charles Baum(Executive Officer, Director)
BoardMichael Goller(Director)Reid Huber(Director)inPeter Thompson(Director)
Co-investorsEcoR1 CapitalOrbiMedRA CapitalOsage University PartnersThird Rock Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.